

Development of a Novel ADC Candidate Targeting ITGB4 through Lead Optimization and Initiation of Preclinical Development

Genome & Company
GENOME & CO

ONCOLOGY	Candidate
----------	-----------

Product Type	Antibody
Indication	Solid tumor
Target	ITGB4 x TROP2
MoA(Mechanism of Action)	• Tumor-selective dual targeting: bispecific ADC that targets the co-expression of ITGB4 and TROP2, which is prevalent in solid tumors but minimal in normal tissues. • Precision cytotoxicity: upon dual binding, the ADC-target complex is internalized to release potent payloads within cancer cells, maximizing efficacy while minimizing systemic toxicity.
Competitiveness	• Enhanced therapeutic index: by targeting dual-positive cells, our candidate overcomes the on-target/off-tumor toxicity limitations of conventional TROP2 ADCs. • First-in-class potential: addresses high unmet needs in various cancers through a superior tumor-selective strategy compared to existing mono-specific competitors.
Development Stage	Candidate
Route of Administration	Intravenous

Any unauthorized distribution or reproduction of this material is strictly prohibited.